N
Novome Biotechnologies
Operates in the technology industry
About Novome Biotechnologies
Novome Biotherapeutics is a biotech startup that specializes in engineering cell therapies to combat chronic diseases. The company operates in the healthcare market, specifically in the field of synthetic biology and microbiome therapeutics. Novome's unique approach involves the use of Genetically Engineered Microbial Medicines (GEMMs), which are microbes engineered to colonize the gut and perform specific therapeutic activities.
Read full description
The company's business model revolves around the development and commercialization of these GEMMs. The microbes are designed to colonize the gut for an extended period, with their abundance maintained and adjusted through a daily dose of a prebiotic polysaccharide. This approach allows for sustained and effective therapies for chronic diseases.
Novome's primary clients are patients suffering from chronic diseases, who stand to benefit from their innovative therapies. The company generates revenue through the development, clinical testing, and eventual sale of these therapies.
Their lead program, NOV-001, has already demonstrated safety and controllable engraftment in a Phase 1 study involving healthy volunteers. This therapy is currently being studied further, indicating the company's progress in bringing its innovative solutions to market.
In summary, Novome Biotherapeutics is a pioneering biotech company that leverages synthetic biology to engineer cell therapies, offering a novel approach to treating chronic diseases.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 61.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Microbiology, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Novome Biotechnologies.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2022 | $44M | $174M | Alexandria Venture Investments · Touchdown Ventures · Navian Investment Group · Colorcon Ventures | ↗ |
| SERIES AOther financing | Jan 2020 | $33M | $132M | Alta Partners · DCVC · 5AM Ventures · Alexandria Venture Investments | — |
Growth signals
Latest recorded traffic for Novome Biotechnologies is 270 monthly website visits, down 37.2% over the last three months. Novome Biotechnologies's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
5AM Ventures
US National Science Foundation
Series A8 investors entered at this stage
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novome Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novome Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.